ZA200401044B - Human mini-antibody cytotoxic for tumor cells which express the ErbB2 receptor. - Google Patents

Human mini-antibody cytotoxic for tumor cells which express the ErbB2 receptor. Download PDF

Info

Publication number
ZA200401044B
ZA200401044B ZA200401044A ZA200401044A ZA200401044B ZA 200401044 B ZA200401044 B ZA 200401044B ZA 200401044 A ZA200401044 A ZA 200401044A ZA 200401044 A ZA200401044 A ZA 200401044A ZA 200401044 B ZA200401044 B ZA 200401044B
Authority
ZA
South Africa
Prior art keywords
cells
erbicin
erbb2
human
preparation
Prior art date
Application number
ZA200401044A
Other languages
English (en)
Inventor
Giuseppe D Alessio
Renata Piccoli
Claudia De Lorenzo
Palmer Donald Balfour
Ritter Mary Alice
Original Assignee
Univ Napoli Federico Ii
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Napoli Federico Ii filed Critical Univ Napoli Federico Ii
Publication of ZA200401044B publication Critical patent/ZA200401044B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ZA200401044A 2001-07-10 2004-02-09 Human mini-antibody cytotoxic for tumor cells which express the ErbB2 receptor. ZA200401044B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT2001RM000408A ITRM20010408A1 (it) 2001-07-10 2001-07-10 Mini-anticorpo umano citotossico per cellule tumorali che esprimono il recettore erbb2.

Publications (1)

Publication Number Publication Date
ZA200401044B true ZA200401044B (en) 2004-10-22

Family

ID=11455653

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200401044A ZA200401044B (en) 2001-07-10 2004-02-09 Human mini-antibody cytotoxic for tumor cells which express the ErbB2 receptor.

Country Status (13)

Country Link
US (2) US7585952B2 (de)
EP (1) EP1432737B1 (de)
AT (1) ATE445646T1 (de)
CA (1) CA2453435A1 (de)
DE (1) DE60234041D1 (de)
DK (1) DK1432737T3 (de)
ES (1) ES2334895T3 (de)
IT (1) ITRM20010408A1 (de)
NZ (1) NZ531035A (de)
PT (1) PT1432737E (de)
SI (1) SI1432737T1 (de)
WO (1) WO2003006509A2 (de)
ZA (1) ZA200401044B (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITFI20010114A1 (it) * 2001-06-22 2002-12-22 Univ Firenze Glicopeptidi,loro preparazione e loro uso nella diagnosi o nel trattamento terapeutico della sclerosi multipla
ES2710439T3 (es) 2005-01-21 2019-04-25 Genentech Inc Dosificación fija de anticuerpos HER
KR101253576B1 (ko) 2005-02-23 2013-04-11 제넨테크, 인크. Ｈｅｒ 이량체화 억제제를 이용한 암 환자에서의 질환진행까지의 시간 또는 생존의 연장
US20100015661A1 (en) * 2006-04-21 2010-01-21 Mab-Factory Gmbh Antibody-rnase-conjugate
JP5638804B2 (ja) * 2006-08-04 2014-12-10 アストラゼネカ アクチボラグ ＥｒｂＢ２に対する抗体
EP2899541A1 (de) 2007-03-02 2015-07-29 Genentech, Inc. Voraussage der Reaktion auf einen HRE-Dimerisationshemmer auf Basis niedriger HER3-Expression
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
CA2690334C (en) 2007-06-08 2017-02-14 Genentech, Inc. Gene expression markers of tumor resistance to her2 inhibitor treatment
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
SG10201402742YA (en) 2009-03-20 2014-08-28 Genentech Inc Bispecific anti-her antibodies
JP5705836B2 (ja) 2009-05-29 2015-04-22 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Ｈｅｒ２を発現する胃癌患者のｈｅｒ２シグナル伝達のためのモジュレーター
KR20130000384A (ko) 2010-02-18 2013-01-02 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 뉴레귤린 길항제 및 암의 치료에서의 그의 용도
US9169328B2 (en) 2010-03-26 2015-10-27 Memorial Sloan Kettering Cancer Center Antibodies to MUC16 and methods of use thereof
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
US20130245233A1 (en) 2010-11-24 2013-09-19 Ming Lei Multispecific Molecules
US20120148559A1 (en) 2010-12-01 2012-06-14 Board Of Regents The University Of Texas System Compositions and method for deimmunization of proteins
JP5766296B2 (ja) 2010-12-23 2015-08-19 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ポリペプチド−ポリヌクレオチド複合体、およびエフェクター成分の標的化された送達におけるその使用
US20140363438A1 (en) 2011-08-17 2014-12-11 Genentech, Inc. Neuregulin antibodies and uses thereof
US9327023B2 (en) 2011-10-25 2016-05-03 The Regents Of The University Of Michigan HER2 targeting agent treatment in non-HER2-amplified cancers having HER2 expressing cancer stem cells
AU2012346540C1 (en) 2011-11-30 2019-07-04 Genentech, Inc. ErbB3 mutations in cancer
WO2013083810A1 (en) 2011-12-09 2013-06-13 F. Hoffmann-La Roche Ag Identification of non-responders to her2 inhibitors
RU2014136886A (ru) 2012-03-27 2016-05-20 Дженентек, Инк. Диагностика и виды лечения, связанные с ингибиторами her3
JP6998646B2 (ja) 2012-11-30 2022-02-04 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Ｐｄ－ｌ１阻害剤併用療法を必要とする患者の同定
US9738726B2 (en) 2013-06-11 2017-08-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services HER2-specific monoclonal antibodies and conjugates thereof
WO2015031119A1 (en) 2013-08-26 2015-03-05 Health Research, Inc. Method for prophylaxis and/or treatment of erbb2 positive cancers
SG11201608192SA (en) 2014-04-11 2016-10-28 Medimmune Llc Bispecific her2 antibodies
SG10201913680PA (en) 2014-05-29 2020-03-30 Macrogenics Inc Tri-specific binding molecules that specifically bind to multiple cancer antigens and methods of use thereof
TWI695011B (zh) 2014-06-18 2020-06-01 美商梅爾莎納醫療公司 抗ｈｅｒ２表位之單株抗體及其使用之方法
TWI693232B (zh) 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
CN107075490A (zh) 2014-08-20 2017-08-18 健康研究公司 用于预防和/或治疗erbb1阳性癌症的方法
AP2017009823A0 (en) 2014-09-26 2017-03-31 Macrogenics Inc Bi-specific monovalent diabodies that are capable of binding cd19 and cd3, and uses thereof
CA2979976A1 (en) 2015-03-17 2016-09-22 Memorial Sloan Kettering Cancer Center Anti-muc16 antibodies and uses thereof
SG10201601719RA (en) 2016-03-04 2017-10-30 Agency Science Tech & Res Anti-LAG-3 Antibodies
WO2017194554A1 (en) 2016-05-10 2017-11-16 Inserm (Institut National De La Sante Et De La Recherche Medicale) Combinations therapies for the treatment of cancer
SG10201603721TA (en) 2016-05-10 2017-12-28 Agency Science Tech & Res Anti-CTLA-4 Antibodies

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07309780A (ja) * 1994-03-02 1995-11-28 N Bii T Kk 抗癌剤
US5795961A (en) * 1995-02-14 1998-08-18 Ludwig Institute For Cancer Research Recombinant human anti-Lewis b antibodies
GB9805660D0 (en) * 1998-03-18 1998-05-13 Unichema Chemie Bv Improvements in and relating to fatty acid metabolism
US6135941A (en) 1998-03-27 2000-10-24 Incyte Pharmaceuticals, Inc. Human immune system associated molecules
US6794128B2 (en) 1998-04-24 2004-09-21 The Regents Of The University Of California Methods of selecting internalizing antibodies
US7244826B1 (en) 1998-04-24 2007-07-17 The Regents Of The University Of California Internalizing ERB2 antibodies
GB9809280D0 (en) 1998-04-30 1998-07-01 Rpms Technology Ltd Immunosupression
AU6841300A (en) * 1999-08-26 2001-03-19 Morphosys Ag Human antibodies or fragments thereof binding to hla-cw6
AU7676300A (en) * 1999-10-12 2001-04-23 Cambridge Antibody Technology Limited Human anti-adipocyte monoclonal antibodies and their use

Also Published As

Publication number Publication date
ES2334895T3 (es) 2010-03-17
US20100173978A1 (en) 2010-07-08
WO2003006509A2 (en) 2003-01-23
EP1432737B1 (de) 2009-10-14
SI1432737T1 (sl) 2010-02-26
DE60234041D1 (de) 2009-11-26
US20070258985A1 (en) 2007-11-08
PT1432737E (pt) 2010-02-17
US8227585B2 (en) 2012-07-24
CA2453435A1 (en) 2003-01-23
DK1432737T3 (da) 2010-02-08
US7585952B2 (en) 2009-09-08
ITRM20010408A1 (it) 2003-01-10
NZ531035A (en) 2005-04-29
WO2003006509A3 (en) 2003-11-20
ATE445646T1 (de) 2009-10-15
ITRM20010408A0 (it) 2001-07-10
EP1432737A2 (de) 2004-06-30

Similar Documents

Publication Publication Date Title
US8227585B2 (en) Human mini-antibody cytotoxic for tumor cells which express the ERBB2 receptor
KR101287777B1 (ko) 가용성 ｃｅａ에 대한 내성을 가지는 약학적 조성물
KR101103218B1 (ko) 종양 괴사 인자-알파에 대한 단일 도메인 항체 및 그 용도
De Lorenzo et al. A new human antitumor immunoreagent specific for ErbB2
US20040242851A1 (en) Bispecific antibodies that bind to vegf receptors
KR20190055008A (ko) 항-her2 항체 또는 그의 항원 결합 단편, 및 이를 포함하는 키메라 항원 수용체
US20040259156A1 (en) Bispecific immunoglobulin-like antigen binding proteins and method of production
US20100240100A1 (en) Human antibodies that have mn binding and cell adhesion-neutralizing activity
US20090070890A1 (en) Product
CN107108737B (zh) c-met特异性人抗体及其制备方法
KR102005452B1 (ko) 암 예방 또는 치료용 약학적 조성물
CN110431150A (zh) 抗体分子-药物偶联物及其用途
HUE030733T2 (en) Antibodies specifically binding to the epidermal growth factor receptor
KR102783248B1 (ko) Cd55에 대한 신규 항체 및 이의 용도
AU2002333238B2 (en) Human mini-antibody cytotoxic for tumor cells which express the ErbB2 receptor
WO2004003211A1 (en) Bispecific antibodies that bind to vegf receptors
AU2002333238A1 (en) Human mini-antibody cytotoxic for tumor cells which express the ErbB2 receptor
JP7619582B2 (ja) Ｃｄ５５に対する新規抗体及びその用途
RU2822550C9 (ru) Антитело против клаудина 18.2 и его применение
KR20250160360A (ko) 항-b7h3 항체 및 사용 방법
KR101926834B1 (ko) 항-dr5 항체 및 그의 용도
HK40082756A (en) Muc1* antibodies
CN117192118A (zh) 一种抗cldn 18.2和cd47的双特异性抗体治疗疾病的用途